Page 5,405«..1020..5,4045,4055,4065,407..5,4105,420..»

"Leadership" PU College of Pharmacy Recruitment – Video

Posted: Published on April 24th, 2013

"Leadership" PU College of Pharmacy Recruitment Produced by SILO Studios Like SILO Studios on Facebook! https://www.facebook.com/SiloStudios CLIENT: Purdue University College of Pharmacy http://www.pharmac... By: SILOStudios2013 … Continue reading

Posted in Pharmacy | Comments Off on "Leadership" PU College of Pharmacy Recruitment – Video

University of Utah College of Pharmacy Grand Opening–4-12-13 – Video

Posted: Published on April 24th, 2013

University of Utah College of Pharmacy Grand Opening--4-12-13 By: UofUHealthCare … Continue reading

Posted in Pharmacy | Comments Off on University of Utah College of Pharmacy Grand Opening–4-12-13 – Video

"DMC Upside:" Pharmacy Schools Visit – Video

Posted: Published on April 24th, 2013

"DMC Upside:" Pharmacy Schools Visit On April 5, 2013, representatives from the Texas A M University Kingsville-Irma Lerma Rangel College of Pharmacy, University of Houston-College of Pharmacy a... By: delmarcollege … Continue reading

Posted in Pharmacy | Comments Off on "DMC Upside:" Pharmacy Schools Visit – Video

CVS Pharmacy Robberies – Video

Posted: Published on April 24th, 2013

CVS Pharmacy Robberies The Dallas Police Crimes Against Persons Division is asking for the public's assistance in identifying and locating the suspect involved in two CVS Pharmacy ... By: DallasPoliceDept … Continue reading

Posted in Pharmacy | Comments Off on CVS Pharmacy Robberies – Video

Power Shifts In Pharmacy Benefit Manager Landscape Impact Pharmaceutical Companies

Posted: Published on April 24th, 2013

NASHVILLE, Tenn., April 24, 2013 /PRNewswire/ --HealthLeaders-InterStudy, the leading provider of managed care market intelligence, analyzes several streams of proprietary data on Pharmacy Benefit Managers (PBMs) to pull out key trends and the accompanying implications for pharmaceutical companies. PBMs are stepping up their game in 2013developing leaner, discounted pharmacy networks, adding sophistication to clinical programs and applying a host of management strategies on specialty drugs. Ongoing consolidation in the industry has concentrated power in two big PBMsExpress Scripts and CVS Caremarkwhich now control pharmacy benefits for more than 60 percent of the insured members enrolled in U.S. managed care plans. Express Scripts alone commands nearly half the U.S. commercial market share, but will give up a substantial portion of that market share to UnitedHealth Group's PBM by the end of 2013. "As midmarket competition heats up, PBMs like Catamaran and Prime Therapeutics become more important to pharmaceutical companies planning a market access strategy," explains Chris Lewis, Senior Market Analyst at HealthLeaders-InterStudy, "and a clear grasp of the implications of what's happening in the industry across the board becomes vital." HealthLeaders-InterStudy's newly released PBM Landscape Report highlights key strategies of PBMs, assesses important players and the distinctive competencies they bringand anticipates … Continue reading

Posted in Pharmacy | Comments Off on Power Shifts In Pharmacy Benefit Manager Landscape Impact Pharmaceutical Companies

University of Maryland Professor Earns Chalmers Distinguished Pharmacy Educator Award

Posted: Published on April 24th, 2013

ALEXANDRIA, Va.--(BUSINESS WIRE)-- The American Association of Colleges of Pharmacy (AACP) will honor Mary Lynn McPherson, Pharm.D., BCPS, CPE, professor and vice-chair for academic affairs in the Department of Pharmacy Practice and Science at the University of Maryland School of Pharmacy, for her excellence as a teacher, her outstanding achievements as a researcher and scholar, and her overall impact on pharmacy education and the profession. She will receive the Robert K. Chalmers Distinguished Pharmacy Educator Award on July 14 during the Opening General Session at the AACP Annual Meeting, Pharmacy Education 2013, in Chicago, Illinois. With so many exceptional pharmacy educators in the United States, I am especially honored and humbled to have been chosen for this prestigious award, said McPherson. I am passionate about working with my colleagues to prepare student pharmacists not only for graduation but for the impact they surely will make in whatever paths they choose for their pharmacy careers. Over the course of her 26-year career, McPherson has amassed an accomplished teaching portfolio and a highly-regarded reputation among Marylands students and faculty. She has led the development and/or redesign of many courses in the schools curriculum, using cutting-edge instructional methods to effectively teach courses such … Continue reading

Posted in Pharmacy | Comments Off on University of Maryland Professor Earns Chalmers Distinguished Pharmacy Educator Award

Assured Pharmacy – 2013 Shareholder Letter

Posted: Published on April 24th, 2013

FRISCO, Texas, April 24, 2013 /PRNewswire/ -- Assured Pharmacy (APHY:OTC Markets), a leading specialty pharmacy group providing prescription medications to sufferers of chronic pain, released its 2013 shareholder letter. Dear Shareholders, Every day, prescription pain medications play a role in improving quality of life for the 75 million people who suffer from chronic pain in the US. With the population aging, cancer incidence increasing and the number of surgeries performed growing, that number is expected to increase significantly in the coming years. The growth of the pain-management market has created opportunities for patients, physicians and the healthcare industry alike, but it has also created challenges: according to the Centers for Disease Control, the illegal use and abuse of controlled medications is an epidemic in the United States. With the global pain management market expected to reach $60 billion in 2015, the safe and efficient distribution of controlled substances will be crucial to maximizing benefits to patients and physicians, while minimizing the challenges and risks. A pharmacy that specializes in the safe distribution of controlled medications with more than eight years of service to patients, physicians and major drug distributors, Assured Pharmacy is more committed than ever to being the leader … Continue reading

Posted in Pharmacy | Comments Off on Assured Pharmacy – 2013 Shareholder Letter

Pharmacy Times Launches New Series to Examine the Effects of Health Care Reform on Pharmacy

Posted: Published on April 24th, 2013

PLAINSBORO, N.J.--(BUSINESS WIRE)-- Pharmacy Times has launched a new series, Directions in Pharmacy, that focuses on navigating health care reform as provisions of the Affordable Care Act are integrated into health plans nationwide. The first of this four-part series debuts this month and provides a road map for pharmacists to follow as the industry rapidly and drastically evolves. The series will reach approximately 25,000 pharmacy owners and managers, chain headquarters personnel, health-system pharmacy directors, managed-care directors, and formulary managers. This series was designed to help everyone who works in pharmacy to better understand the nature and magnitude of the changes underway in the health care system, said Troy Trygstad, PharmD, Ph.D., MBA, co-editor of the series. We hope that our in-depth coverage helps the industry prepare to adapt. The April 2013 issue of Directions in Pharmacy features an in-depth look at the tenets of health care reform that will affect every pharmacist, including increased accountability, a growing focus on prevention, and reduced cost shifting. Future editions will focus on other areas, such as the coordination of care, health care costs, and how technology is changing the way patients interact with their health care teams. The group of experts who provide … Continue reading

Posted in Pharmacy | Comments Off on Pharmacy Times Launches New Series to Examine the Effects of Health Care Reform on Pharmacy

Chimerix Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection

Posted: Published on April 24th, 2013

CMX001 demonstrated potential clinical utility in prevention of CMV infection in Phase 2 SUPPRESS trial anticipated to begin dosing mid-2013 with topline data expected in 2015 DURHAM, N.C., April 24, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the final study design for the Phase 3 SUPPRESS trial of CMX001 in the prevention of cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT). CMX001 is an investigational oral nucleotide analog lipid-conjugate that has shown broad-spectrum antiviral activity against double-stranded DNA (dsDNA) viruses including all of the herpesviruses, adenoviruses and polyomaviruses. Since the End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in May 2012, Chimerix has been working closely with the FDA on the study design of the Phase 3 SUPPRESS trial, and has now finalized the population, specifics and timing of the primary and multiple secondary endpoints, as well as the dose and duration of CMX001 therapy. Initial study designs considered that two active doses of CMX001, 100 mg twice weekly and 75 mg twice weekly, be carried forward into the Phase 3 trial in order to mitigate … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Chimerix Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection

ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular Degeneration

Posted: Published on April 24th, 2013

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardts macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was injected with 150,000 hESC-derived RPE cells, as compared with the 100,000-cell dose used in patients of the second cohort. The surgery was performed on Friday, April 19, without any complications, and the patient is recovering uneventfully. Europe represents a huge potential market for us, the worlds largest after the U.S., so we are particularly pleased to now be past the halfway point in all three of our clinical trials on both continents, commented Gary Rabin, chairman and CEO of ACT. SMD affects as many as 100,000 patients in the U.S. and Europe. Moreover, as previously announced, the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) officially granted our hESC-derived RPE cells orphan medicinal product designation for the treatment of SMD. We expect this will provide a number of benefits once our SMD treatment has made the … Continue reading

Posted in Stem Cell Human Trials | Comments Off on ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular Degeneration

Page 5,405«..1020..5,4045,4055,4065,407..5,4105,420..»